Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eurand reveals positive phase III data
Zentase met all primary and secondary endpoints in two phase III trials. The studies were designed to determine whether the product candidate could alleviate serious malabsorption associated with
Zentase met all primary and secondary endpoints in two phase III trials. The studies were designed to determine whether the product candidate could alleviate serious malabsorption associated with
Campath is currently approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been previously treated with an alkylating agent and have failed fludarabine
The application seeks approval to market the drug for the treatment of non-small cell lung cancer patients with brain metastases. The company received a refuse to file letter
Roche Diagnostics said the acquisition would allow it to expand its immunochemistry business from the human diagnostics field into new market segments such as life science research, life
The study clearly demonstrated a robust protective effect in mice treated with the synDNA vaccine whereas all the untreated control animals died after both groups were challenged with
The primary objectives of the trial are a partial or complete tumor response and stable disease. Secondary outcomes include progression-free survival and quality of life. The study will
The combination drug, known as Trexima, contains the treatments Imitrex and naproxen sodium, and is being developed by GlaxoSmithKline and Pozen. “Recent research suggests that migraine is more
Until recently all medicines were distributed through a number of competing wholesalers. However, in March 2007 Pfizer began selling prescription drugs solely through one wholesaler, Unichem, a division
The Womens Health Initiative (WHI) study conducted five years ago led many menopausal women to abandon hormone therapy because of the suggestion that the drug increased the risk
The study examined patients treated with Erbitux in combination either with cisplatin plus 5-fluorouracil (5-FU) or carboplatin plus 5-FU, compared to patients treated with cisplatin plus 5-FU or